Navigation Links
Sinovac to Present at 23rd Annual Piper Jaffray Health Care Conference and HK/China Mini Conference 2011 (Healthcare)
Date:11/23/2011

BEIJING, Nov. 23, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that management is scheduled to present at the 23rd Annual Piper Jaffray Health Care Conference that will be held on November 29th and 30th at The New York Palace in New York City, and to participate in HK/China Mini Conference 2011 (Healthcare) on December 1, 2011 at Island Shangri-La Hotel, Hong Kong.  

Ms. Helen Yang, Sinovac's Investor Relations Director, will present on November 30th at 10:30 am ET at the 23rd Annual Piper Jaffray Health Care Conference and will be participating in one-on-one meetings.

Ms. Nan Wang, Sinovac's Interim CFO and Chris Lee, Investor Relations, will be participating in one-on-one meetings at HK/China Mini Conference 2011 (Healthcare) on December 1, 2011.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), pneumococcal polysaccharides, human rabies, HIB, rotavirus and epidemic meningitis, chickenpox and mumps & rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines, and has launched its internally developed inactivated rabies vaccine in China.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel:  +86-10-8279-9871/9659
Fax:  +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington
The Ruth Group
Tel:  +1-646-536-7017
Email: scarrington@theruthgroup.com

Media
Victoria Aguiar
The Ruth Group
Tel:  +1-646-536-7013
Email:  vaguiar@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. /C O R R E C T I O N -- Sinovac Biotech Ltd./
2. Sinovac Reports Unaudited Third Quarter 2011 Financial Results
3. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
4. Sinovac to Host Conference Call to Report Third Quarter 2011 Unaudited Financial Results
5. Sinovac Reports Unaudited Second Quarter 2011 Financial Results
6. Sinovac Announces Management Changes
7. Sinovac Holds 2011 Annual Shareholders Meeting
8. Sinovac Appoints Kenneth Lee to Board of Directors
9. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
10. Sinovac Reports Unaudited First Quarter 2011 Financial Results
11. Sinovac Presents at Two Investor Conferences in May 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... CITY , March 29, 2017  Bodycad ... and Drug Administration (FDA) 510(k) clearance for its ... of this truly personalized orthopaedic restoration. Bodycad is ... for a joint reconstruction implant system. ... to optimize personalized restoration of the patient,s unique ...
(Date:3/29/2017)... Global intravenous (IV) iron and oral iron market ... at a CAGR of 5%. Iron drugs ... treat anemia or other iron deficiencies. Oral iron supplements are ... in some cases, oral administrations are not capable of maintaining ... therapy comes into the picture. Global Intravenous (IV) ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Italy ... report to their offering. ... Proton Therapy Market in Italy will double by ... currently three proton therapy centers in Italy that ... Italy , the first patients were treated with proton beams in ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare partner ... with prominent executives from both inside and outside the cannabis industry. , Joining ... , who has more than twenty years of business leadership and investment experience in ...
(Date:3/29/2017)... ... 29, 2017 , ... HealthCareMandA.com will host an important webinar — Home Health ... ET. A recording of the webinar will also be made available following its live ... hospice companies are still popular targets for healthcare investors. This highly fragmented sector bounced ...
(Date:3/29/2017)... ... 29, 2017 , ... Immunotherapy has emerged as one of the most promising ... to be the next revolution in our fight against this complex disease. One of ... immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... have easier access to the robotic-assisted total-hip and partial-knee replacement surgeries that ... surgeons at Forbes Hospital and Jefferson Hospital recently started performing these surgeries ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of ... Julie Taffet Moelis, W’81, have made a $10 million gift to establish the ... that will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates whose ...
Breaking Medicine News(10 mins):